Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kiniksa Pharmaceuticals (KNSA)
NASDAQ:KNSA
RESEARCH TOOLSreports
Holding KNSA?
Track your performance easily
KNSA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$16.56 - $28.15
Previous Close$19.94
Volume73.90K
Average Volume (3M)307.75K
Market Cap
$1.46B
Enterprise Value$1.25B
Total Cash (Recent Filing)$223.78M
Total Debt (Recent Filing)$10.60M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Feb 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding72,201,565
10 Day Avg. Volume313,888
30 Day Avg. Volume307,745
Standard Deviation0.16
R-Squared0.00762
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)3.30
Price to Sales (P/S)3.75
Price to Cash Flow (P/CF)-161.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.36
Enterprise Value/Gross Profit5.27
Enterprise Value/Ebitda-101.86
Forecast
1Y Price Target
$36.67Price Target Upside83.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Kiniksa Pharmaceuticals News
Ownership Overview
7.94% Insiders
17.66% Mutual Funds
49.84% Other Institutional Investors
11.83% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KNSA FAQ
What was Kiniksa Pharmaceuticals’s price range in the past 12 months?
Kiniksa Pharmaceuticals lowest stock price was $16.56 and its highest was $28.15 in the past 12 months.
What is Kiniksa Pharmaceuticals’s market cap?
Currently, no data Available
When is Kiniksa Pharmaceuticals’s upcoming earnings report date?
Kiniksa Pharmaceuticals’s upcoming earnings report date is Feb 26, 2025 which is in 62 days.
How were Kiniksa Pharmaceuticals’s earnings last quarter?
Kiniksa Pharmaceuticals released its earnings results on Oct 29, 2024. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of $0.023 by -$0.203.
Is Kiniksa Pharmaceuticals overvalued?
According to Wall Street analysts Kiniksa Pharmaceuticals’s price is currently Undervalued.
Does Kiniksa Pharmaceuticals pay dividends?
Kiniksa Pharmaceuticals does not currently pay dividends.
What is Kiniksa Pharmaceuticals’s EPS estimate?
Kiniksa Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kiniksa Pharmaceuticals have?
Kiniksa Pharmaceuticals has 41,566,826 shares outstanding.
What happened to Kiniksa Pharmaceuticals’s price movement after its last earnings report?
Kiniksa Pharmaceuticals reported an EPS of -$0.18 in its last earnings report, missing expectations of $0.023. Following the earnings report the stock price went down -15.694%.
Which hedge fund is a major shareholder of Kiniksa Pharmaceuticals?
Among the largest hedge funds holding Kiniksa Pharmaceuticals’s share is Fairmount Funds Management Llc. It holds Kiniksa Pharmaceuticals’s shares valued at 80M.
---
Kiniksa Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.67 (83.90% Upside)
$36.67 (83.90% Upside)
Blogger Sentiment
Bullish
KNSA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 82.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.32%
12-Months-Change
Fundamentals
Return on Equity
-2.15%
Trailing 12-Months
Asset Growth
14.95%
Trailing 12-Months
Company Description
Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason, and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.
---
KNSA Company Deck
---
KNSA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and increased sales guidance, driven by high prescriber satisfaction and effective educational initiatives. However, challenges remain with net losses and patient misdiagnosis rates. Overall, the positive aspects of revenue growth and strategic initiatives outweigh the negatives.Read More>---
KNSA Stock 12 Month Forecast
Average Price Target
$36.67
▲(83.90% Upside)
Technical Analysis
Best Analysts Covering KNSA
1 Year
1 Year Success Rate
9/11 ratings generated profit
1 Year Average Return
+24.95%
assigned a buy rating 8 months ago
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +24.95% per trade.
---